ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study.
Michael MarisGilles SallesWon Seog KimTae Min KimRoger M LyonsMartha ArellanoReem KarmaliGary SchillerElizabeth CullCamille N AbboudConnie BatleviIoannis KagiampakisMarlon C RebelattoYoung LeeLyndon C KirbyFujun WangJohn BothosDanielle M TownsleyAmir T FathiVincent RibragPublished in: Targeted oncology (2024)
Thrombocytopenia and neutropenia limited repeat dosing. Although limited clinical activity was detected, the dose-escalation phase was stopped early without establishing an MTD. The study was registered with ClinicalTrials.gov (NCT03106428).